ALS2CL, the novel protein highly homologous to the carboxy-terminal half of ALS2, binds to Rab5 and modulates endosome dynamics  by Hadano, Shinji et al.
FEBS Letters 575 (2004) 64–70 FEBS 28783ALS2CL, the novel protein highly homologous to the carboxy-terminal
half of ALS2, binds to Rab5 and modulates endosome dynamics
qShinji Hadanoa,b, Asako Otomoa, Kyoko Suzuki-Utsunomiyaa, Ryota Kunitab,
Yoshiko Yanagisawab, Junko Showguchi-Miyataa, Hikaru Mizumurab, Joh-E Ikedaa,b,c,*
aDepartment of Molecular Neuroscience, The Institute of Medical Sciences, Tokai University, Isehara, Kanagawa 259-1193, Japan
bSolution Oriented Research for Science and Technology (SORST), Japan Science and Technology Agency, Tokai University School of Medicine,
Isehara, Kanagawa 259-1193, Japan
cDepartment of Paediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ont., Canada K1H 8M5
Received 10 May 2004; revised 5 July 2004; accepted 27 July 2004
Available online 7 September 2004
Edited by Lukas HuberAbstract ALS2, the causative gene product for juvenile reces-
sive amyotrophic lateral sclerosis (ALS2), is a guanine-nucleo-
tide exchange factor for the small GTPase Rab5. Here, we
report a novel ALS2 homologous gene, ALS2 C-terminal like
(ALS2CL), which encodes a 108-kD ALS2CL protein. ALS2CL
exhibited a speciﬁc but a relatively weak Rab5-GEF activity
with accompanying rather strong Rab5-binding properties. In
HeLa cells, co-expression of ALS2CL and Rab5A resulted in a
unique tubulation phenotype of endosome compartments with
signiﬁcant colocalization of ALS2CL and Rab5A. These results
suggest that ALS2CL is a novel factor modulating the Rab5-
mediated endosome dynamics in the cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Endosome dynamics1. Introduction
Amyotrophic lateral sclerosis (ALS), primary lateral scle-
rosis (PLS), and hereditary spastic paraplegia (HSP) are
neurological disorders, which are characterized by a pro-
gressive motor neuronal degeneration [1,2]. Recently, we and
other groups have identiﬁed the loss-of-functional mutations
in the ALS2 gene, accounting for a number of juvenile re-
cessive motor neuron diseases (MND) including a type of* Correspondence author. Fax: +81-463-91-4993.
E-mail address: joh-e@nga.med.u-tokai.ac.jp (J.-E. Ikeda).
q The cDNA sequences of ALS2CL and Als2cl have been deposited in
DDBJ/EMBL/GenBank Database under Accession Nos. AB107015
and AB107016.
Abbreviations: ALS, amyotrophic lateral sclerosis; PLS, primary
lateral sclerosis; HSP, hereditary spastic paraplegia; MND, motor
neuron disease; ALS2CL, ALS2 carboxy-terminal like; GEF, guanine-
nucleotide exchange factor; RLD, regulator of chromosome conden-
sation-like domain; DH, Dbl homology; PH, pleckstrin homology;
MORN, membrane occupation and recognition nexus; VPS9, vacuolar
protein sorting 9; EEA1, early endosome antigen-1; EGFP, enhanced
green ﬂuorescent protein
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.07.092juvenile ALS (ALS2), juvenile-onset PLS (PLSJ), and in-
fantile-onset ascending hereditary spastic paralysis (IAHSP)
[3–7].
The ALS2 gene encodes a novel 184 kD protein, termed
ALS2 or alsin, comprising three predicted guanine-nucleotide
exchange factor (GEF) domains [3,4]; i.e., regulator of chro-
mosome condensation (RCC1) [8]-like domain (RLD), the Dbl
homology and pleckstrin homology (DH/PH) domains [9], and
a vacuolar protein sorting 9 (VPS9) domain [10,11]. In addi-
tion, eight consecutive membrane occupation and recognition
nexus (MORN) motifs [12] are noted in the region between
DH/PH and VPS9 domains [13]. Recently, we have identiﬁed
the ALS2-associated Rab5-speciﬁc GEF activity that is medi-
ated by the carboxy-terminal MORN/VPS9 domain of ALS2
and also shown that ALS2 localizes preferentially onto the
early endosome compartments in neuronal cells [13]. Since
Rab5 plays crucial roles in clathrin-mediated vesicle endocy-
tosis, traﬃcking, and early endosomal membrane fusion [14],
ALS2 may implicate in the vesicle/membrane dynamics in the
cells through the activation of Rab5.
Here, we report the identiﬁcation and characterization of the
novel ALS2 homologous gene, ALS2 C-terminal like
(ALS2CL/Als2cl), and its gene product ALS2CL.2. Materials and methods
2.1. Cloning of the ALS2 homologous genes
To identify the potential homologs/paralogs for ALS2/Als2 genes,
we conducted BLAST searches [15] on the public databases. Cloning
of the full-length transcripts for the identiﬁed homologous genes, i.e.,
ALS2CL and Als2cl, was performed by a reverse transcriptase (RT)-
polymerase chain reaction (PCR)-based method. Analysis of the
predicted amino acid sequences, including motif/domain identiﬁca-
tion and multiple protein sequence alignment was conducted as
described [3].2.2. Northern blotting
Multiple human adult tissue Northern (MTN) blot (Clontech) was
hybridized with [a-32P]dCTP-labeled open reading frame (ORF)
probes generated from the ALS2CL or ACTB (b-actin) cDNA in
PerfectHyb hybridization solution (Toyobo) at 68 C. Membranes
were washed with 0:1 SSC containing 1% SDS at 65 C and exposed
to X-ray ﬁlm (Bio-MAX, Kodak). The mouse adult tissue MTN blot
(Clontech) was also hybridized with the Als2cl or glyceraldehyde
3-phosphate dehydrogenase (Gapdh) cDNA.blished by Elsevier B.V. All rights reserved.
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All cDNA expression constructs were generated by subcloning the
RT-PCR ampliﬁed fragments into the appropriate vectors. For the
GEF assay, four cDNA fragments; i.e., human ALS2_1018-1657aa
(ALS2_1018-1657), human ALS2CL ORF (ALS2CL_human), and
mouse Als2cl ORF (ALS2CL_mouse), were subcloned into pCI-neo
Mammalian Expression Vector (Promega). For the subcellular locali-
zation studies, human and mouse ALS2CLs, which were fused amino-
terminally with enhanced green ﬂuorescent protein (EGFP), were
generated using pEGFP-C1 (Clontech). The bacterial expression
plasmids encoding the small GTPases and FLAG-tagged human
Rab5A, which have been previously generated [13], were also utilized.
2.4. GEF assay and in vitro binding
GEF assay was conducted as previously described [13]. In vitro
binding experiments were also performed as described [13] with several
modiﬁcations. In brief, puriﬁed Rab5A (4 pmol), which was pre-loaded
with either GDP or GTPcS, or nucleotide-free, was mixed with
FLAG-M2 beads conjugating 4 pmol equivalent of the immunopre-
cipitated FLAG-tagged ALS2CL or ALS2 in 100 ll of a modiﬁed GEF
buﬀer [25 mM Tris–HCl, pH 7.4, 100 mM NaCl, 20 mM MgCl2, 1.5
mM CHAPS, and 0.1% (w/v) skimmed milk] containing 50 lM of
either GDP or GTPcS, or without nucleotides, for 2 h at 30 C. After
washing with 4 1 ml of the same buﬀer, bound Rab5A was co-eluted
with FLAG-ALS2CL protein by the addition of SDS–PAGE sample
buﬀer and detected by Western blotting analysis using appropriate
antibodies.
2.5. Cell culture, transfection, and microscopic observations
HeLa and COS-7 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum (Invitrogen), 100
U/ml penicillin, and 100 lg/ml streptomycin. Cells were transfected
with plasmid constructs using Eﬀectene Transfection Reagent (Qia-
gen). Immunocytochemical detection and image analysis were con-
ducted by Leica TCS_NT confocal-microscope systems (Leica) as
previously described [13].3. Results
3.1. Identiﬁcation of the human ALS2CL and mouse Als2cl
genes
A BLAST search of the GenBank/DDBJ/EMBL database
for potential ALS2/Als2 paralogs and/or homologs revealed
the presence of the genomic segments, mRNAs, and EST se-
quences, which encode a novel protein highly homologous to
the carboxy-terminal half of the human and mouse ALS2
proteins, in human, mouse, and rat genome. Computational
analyses of the DNA sequences by assembling the mRNA and
EST sequences, followed by the comparison with genomic
DNA sequences and mapping, demonstrated that human and
mouse ALS2/Als2 homologous genes comprised 26 exons and
resided within approximately 24.5 kb of the genomic region on
human chromosome 3p21.31 and the 23.2 kb genomic region
on mouse chromosome 9F3, respectively (Fig. 1A). We des-
ignated these human and mouse genes as ALS2 C-terminal
like; ALS2CL (HGNC approved symbol) and Als2cl (MGD
nomenclature committee approved symbol), respectively. The
sequences of the ALS2CL and Als2cl transcripts encompassed
4741 nt (ORF; 2862-nt long) (AB107015) and 5081 nt (ORF;
2859-nt long) (AB107016), and matched with the sequences for
human transcript LOC259173_isoform 1 (NM_147129) and
mouse RN49018 (NM_146228) [16], respectively (Fig. 1A and
B).
3.2. Alternative splicing variants for ALS2CL and Als2cl
In the course of our database searches and RT-PCR based
cloning of the transcribed DNA sequences, an extensive al-ternative splicing of the transcripts, giving rise to at least 17
minor variants of ALS2CL, was noted in human tissues
(Fig. 1B), in addition to the major ALS2CL transcript. Anal-
yses of the ﬂanking DNA sequences for these variants identi-
ﬁed the cryptic acceptor and donor consensus sequences (data
not shown), suggesting that all these variants arose by alter-
native splicing. It was also evident that all these alternative
splicing, resulting in premature stop codons, disrupted the
coding frame for full-length ALS2CL (Fig. 1B). Physiological
signiﬁcances of these extensive splicing events were currently
unknown.
We also identiﬁed ﬁve minor murine variants as follows: (1)
alternative 50-UTR exons ‘a’ and ‘b’ proceeded by exon 2
(Fig. 1A), (2) cryptic three nucleotides insertion (-27_-26ins-
TAG), (3) transcript with intron 13, (4) transcripts with skip-
ping exon 19, and (5) alternative exon ‘c’ between exons 7 and
8 (RIKEN_5830412B02: with skipping exon 19, Fig. 1A).
3.3. Deduced amino acid sequences
Computational predictions have shown that major tran-
scripts for both ALS2CL and Als2cl encode 108-kD proteins,
ALS2CL [953 and 952 amino acids (aa), respectively], com-
prising several domains and motifs including PH, MORN, and
VPS9 (Fig. 2A). Human and mouse ALS2CL proteins showed
a high degree of sequence conservation to each other (81%
identity and 88% similarity), and with the corresponding C-
terminal region of human ALS2 (33% identity and 51% simi-
larity) (Fig. 2B). Interestingly, phylogenetical analysis revealed
that amino acid sequences for ALS2CL were much closer to
that for fugu ALS2 than those for human and mouse ALS2
(data not shown).
3.4. Tissue distribution of the ALS2CL/Als2cl mRNA
Northern blot analysis revealed the ALS2CL transcript of
an approximately 5 kb of the major mRNA in various adult
human tissues with higher expression in both heart and kidney
(Fig. 3A). It is also noted that the band-signals for the
ALS2CL transcript were rather blurred, consistent with the
presence of multiple alternative splicing variants. In contrast, a
single 5 kb discrete band for the mouse Als2cl transcript was
observed in variety of tissues in adult mice with highest in liver
(Fig. 3B).
3.5. Assays of the ALS2CL-associated GEF activity
To analyze the ALS2CL-associated GDP/GTP exchanging
activities, i.e., so-called GEF activities, on the small GTPases,
in vitro GDP dissociation assays were conducted using nine
bacterially produced small GTPases including Rab4A, Rab5A,
Rab5B, Rab5C, Rab7, Rab11A, Rac1, RhoA, and Cdc42. The
ALS2_1018-1657 peptide, which spans the minimum region
associating with Rab5-GEF activity [13], was used as a positive
control. The results showed that human ALS2CL exclusively
catalyzed GDP dissociation on Rab5A, Rab5B, and Rab5C,
as in the cases for ALS2_1018-1657 (Fig. 4A), suggesting that
humanALS2CL retained selective catalytic activity with all the
members of Rab5 family. However, the degree of activities for
ALS2CL was signiﬁcantly lower than that for ALS2_1018-
1657 (Fig. 4A). Interestingly, mouse ALS2CL exhibited almost
no Rab5-GEF activities (Fig. 4A).
To deﬁne the enzymatic kinetics for theRab5GEFactivity, we
next carried out the GDP dissociation assay on Rab5A using a
wide range of concentrations for either ALS2CLs or
Fig. 1. Genomic organization of the human ALS2CL and mouse Als2cl genes. (A) Schematic representation of genomic organizations for human
ALS2CL (upper) and mouseAls2cl (lower) genes.ALS2CL spans approximately 24.5 kb of the genomic region on human chromosome 3p21.31, while
Als2cl covers approximately 23.2 kb of the region on chromosome 9F3. Both genes comprise 26 major exons. Black and gray boxes represent coding
(translated) and non-coding (untranslated) region of major exons (exons 1–26), respectively. Minor alternative exons (A–H for human; a–c for mouse)
are also shown as white boxes. (B) Exon organization of splicing variants for the humanALS2CL transcripts. A single major form and 17 diﬀerentially
spliced minor variants are shown. The positions of translation initiation (ATG) and termination (TGA, TAG, or TAA) codons are shown.
66 S. Hadano et al. / FEBS Letters 575 (2004) 64–70ALS2_1018-1657 (ﬁnal 0–1.6 lM) (Fig. 4B). Both ALS2_1018-
1657 and human ALS2CL revealed the protein concentration-
dependent Rab5-GEF activities with approximately eightfold
lower dissociation constant with human ALS2CL (ALS2_1018-
1657;25 nMvs. humanALS2CL;200 nM).However,mouse
ALS2CL did not show any signiﬁcant Rab5-GEF activities at
any concentrations of the protein (Fig. 4B).
3.6. Interaction of ALS2CL and Rab5
To examine whether the ALS2CL proteins directly interact
with Rab5, we conducted the in vitro binding assays using the
FLAG-M2 pull-down experiments. The amino-terminally
FLAG-tagged ALS2_1018-1657, human ALS2CL, and mouse
ALS2CL were immunoprecipitated in the presence of re-
combinant Rab5A, which was pre-loaded with either GDP orGTPcS, or left unloaded with any nucleotides. Despite the fact
that the ALS2CL proteins showed a low or negligible Rab5-
GEF activity, they bound rather strongly to Rab5A (Fig. 5).
Notably, the ALS2_1018-1657 peptide, which revealed the
higher Rab5-GEF activity (Fig. 4), bound preferentially to the
nucleotide-free form of Rab5A, whereas mouse ALS2CL,
which exhibited no Rab5-GEF activity, interacted non-selec-
tively with any forms of Rab5A. The Rab5A-binding proper-
ties for human ALS2CL demonstrated an intermediate
preferentiality.
3.7. Subcellular localization of ALS2CL
To investigate the subcellular localization of ALS2CL, HeLa
cells were transfected with plasmid expressing either human or
mouse ALS2CL. Ectopically expressed amino-terminally
Fig. 2. Amino acid sequence analysis. (A) Schematic representation of the domains and motifs identiﬁed in the predicted human ALS2CL and ALS2
proteins. (B) ClustalW multiple amino acid sequence alignment of mouse (ALS2CL_C57BL/6; NP_666340, and ALS2CL_BALBc; this study), rat
(ALS2CL_rat; XP_236654), and human (ALS2CL_human; this study) ALS2CL proteins, and the C-terminal portions of human (ALS2_human;
NP_065970), mouse (ALS2_BALBc; NP_082993), and fugu (ALS2_fugu; SINFRUP00000067515) ALS2 proteins. Intron–exon boundaries for
human ALS2CL and ALS2 are also shown. Sequences are numbered with the initiation codon of each protein as #1.
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ALS2CL proteins localized throughout the cells with strong
punctated stainings in cytoplasm. EGFP-fused mouse
ALS2CL also showed similar distribution pattern (Fig. 6C).Co-localization analyses revealed that human ALS2CL par-
tially overlapped with early endosome antigen 1 (EEA1) [17]
immunopositive vesicles and/or early endosomes (Fig. 6D–F),
but not with the late-endosomal/lysosomal markers, LAMP-1
Fig. 3. Northern blot analysis. MTN blots were hybridized with ALS2CL/Als2cl (upper panel) cDNA clones. Filled and open arrowheads indicate
the position of major and minor transcripts, respectively. The lower panel represents the same blots hybridized with (A) the human ACTB (b-actin)
cDNA or (B) the mouse glyceraldehyde 3-phosphate dehydrogenase (Gapdh) cDNA to conﬁrm RNA quality and relative loading. Positions of size-
markers are shown on the left.
Fig. 4. GEF activity assays. (A) In vitro [3H]GDP dissociation assay
for FLAG-tagged ALS2 peptide (ALS2_1018-1657aa; light gray bars),
human ALS2CL (ALS2CL_human; dark gray bars), mouse ALS2CL
(ALS2CL_mouse; black bars), and FLAG-tag alone (empty; as a
control, open bars) on nine diﬀerent small GTPases. Each value rep-
resents the mean and standard deviation of at least three independent
assays. Double asterisk, P<0.001; asterisk, P<0.01 in t tests. (B) In
vitro [3H]GDP dissociation assay on Rab5A in the presence of in-
creasing amount of recombinant ALS2CL and ALS2 proteins. Each
value represents meansS.D. (n¼ 3) of the percentage of [3H]-GDP
bound to Rab5A after 60 min in the presence of given amount either
of ALS2_1018-1657 (diamonds), ALS2CL_human (squares), or
ALS2CL_mouse (triangles).
Fig. 5. In vitro Rab5A binding assay. Nucleotide free (nt-free), GDP
bound (GDP), or GTPcS bound (GTPcS) forms of Rab5A were
incubated with FLAG-M2 beads conjugating FLAG-tagged
ALS2_1018-1657aa, human ALS2CL (ALS2CL_human), or mouse
ALS2CL (ALS2CL_mouse), or with FLAG-M2 beads alone (empty)
as a control. The bound and input Rab5A were detected by immu-
noblotting method using anti-Rab5 antibody. Western blotting anal-
ysis of the FLAG-tagged proteins was also conducted using the
FLAG-M2 antibody.
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shown). However, the degree of EEA1 overlapping was quite
low (<10%), when compared with those for ALS2_660-1657, in
which a high degree (85%) of vesicular co-localization was
observed [13].
3.8. Co-localization of ALS2CL and Rab5A
To investigate whether human ALS2CL co-localized with
Rab5 in vivo, co-transfection of HeLa cells with expression
constructs for EGFP-fused ALS2CL and FLAG-tagged
Rab5A was conducted. The results showed that both proteins
were signiﬁcantly co-distributed onto the vesicular/membra-
nous compartments in cytoplasm, particularly to the leading
edges of the cells (Fig. 6G–I). Notably, co-expression of
ALS2CL and Rab5A frequently (40% of the co-transfected
Fig. 6. Localization of ALS2CL in the cells. (A–C) Subcellular distribution of the ectopically expressed ALS2CL in HeLa cells (A, FLAG-tagged
human ALS2CL; B, EGFP-fused human ALS2CL; C, EGFP-fused mouse ALS2CL). (D–F) Partial co-localization of the human ALS2CL onto
EEA1-positive endosomes (D, EGFP-fused human ALS2CL; E, endogenous EEA1; F, merged image). (G–L) Co-transfection of the EGFP-fused
human ALS2CL and FLAG-tagged Rab5A expression constructs in HeLa cells (G and J, EGFP-fused human ALS2CL; H and K, FLAG-tagged
Rab5A; I and L, merged images). The representative images for the cells exhibiting vesicular (G–I) and tubular membranous (arrows; J–L) dis-
tributions are shown. Arrowheads indicate the leading edges of the cells.
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compartments, showing a tubulation and/or elongation with
accompanying extensive co-localization of ALS2CL and
Rab5A (Fig. 6J–L).4. Discussion
In this study, we newly identiﬁed the ALS2 homologous
gene, ALS2CL and Als2cl. ALS2CL and Als2cl map to the
syntenic chromosomal regions on human chromosome 3p21and mouse chromosome 9F3, respectively, both comprising 26
major exons. The intron–exon boundaries for ALS2CL and
Als2cl, and those for the homologous regions of ALS2/Als2
were nearly completely preserved. Further, analysis of the
predicted amino acid sequences revealed a high level of se-
quence similarity throughout the entire region of ALS2CL and
the C-terminal portion of the ALS2 proteins, indicating that
ALS2CL/Als2cl and ALS2/Als2 were evolutionally conserved
genes evolved from a common ancestry of origin. Notably,
ALS2CL/Als2cl lack several exons corresponding to those
encoding N-terminal RLD for ALS2, suggesting that the N-
70 S. Hadano et al. / FEBS Letters 575 (2004) 64–70terminal portion of ALS2 can be independently evolved. In
spite of such structural conservation, our results demonstrate
that the molecular functions for ALS2CL and the C-terminal
homologous region of ALS2 seem to be slightly diﬀerent.
Previously, we have shown that enzymatic activity for the
activation of Rab5 GTPase is retained in the C-terminal por-
tion of human ALS2 comprising MORN/VPS9 domain, and
that either deletion of MORN motifs or the mutation in the
evolutionally conserved amino acid residues in VPS9 domain
resulted in the loss of its catalytic activity [13]. In this study, we
demonstrated that, although human ALS2CL showed a simi-
lar catalytic speciﬁcity on the small GTPases as that for human
ALS2, the level of its Rab5-GEF activity was signiﬁcantly
lower than that for ALS2, or even at almost negligible levels.
On the other hand, ALS2CL, especially an enzymatically al-
most-inactive mouse ALS2CL, exhibited a stronger binding to
Rab5 than ALS2, in a nucleotide state-independent manner.
These results suggest that ALS2CL may act as a functional
modulator in the Rab5-mediated enzymatic reactions, whilst
those actions are slightly diﬀerent from that for ALS2.
We have previously also shown that overexpression of the C-
terminal human ALS2 peptide containing 660–1657 aa, span-
ning a homologous region corresponding to entire ALS2CL,
localizes onto the Rab5/EEA1-positive early endosomal com-
partments, and induces the striking enlargement of endosomes,
which is mediated through the Rab5GEF activity inherent to
the MORN/VPS9 region of ALS2 [13]. On the other hand,
ectopically expressed ALS2CLs localize in both nucleus and
cytoplasm with strong punctated stainings that are extensively
overlapped with Rab5A but not with EEA1, suggesting that the
ALS2CL proteins preferentially localize to the Rab5-positive/
EEA1-negative vesicles and/or endosome sub-compartments.
Further, co-expression of human ALS2CL and Rab5A caused
unique morphological changes in endosomal compartments,
which were characterized by membrane tubulation rather than
enlargement. Taken together, these results again support the
biochemical notion that ALS2CL and ALS2 mediate similar
but slightly diﬀerent molecular functions in the cells.
Several recent studies demonstrated that the similar tubular
endosome phenotypes were elicited under certain experimental
conditions, such as in the presence of wortmannin, an inhibitor
for phosphatidylinositol-3 kinase [20], or brefeldin A, a potent
inhibitor of traﬃcking through the secretory pathway [21], as
well as by the overexpression of dominant positive Rab4 small
GTPase [22]. As each of these treatments leads to the im-
pairment of normal endosomal membrane traﬃcking [20–22],
overexpression of human ALS2CL may also disturb the nor-
mal vesicle/membrane traﬃcking possibly through the actions
associating with a lower Rab5-GEF activity with a higher
Rab5 binding property for the ALS2CL proteins.
In summary, our results demonstrate that ALS2CL/Als2cl
and ALS2/Als2 are evolutionally conserved genes, and that
their products, ALS2CL and ALS2, play overlapping but
slightly distinctive roles on the Rab5-mediated vesicle/mem-
brane traﬃcking and dynamics in the cells. Thus, it is possible
that ALS2CL modulates the ALS2-mediated molecular and
cellular functions either directly or indirectly, thereby impli-
cating in the phenotypic variations seen in patients with ALS2/
PLSJ/IAHSP. Further dissection of molecular and cellular
functions for ALS2CL as well as those for ALS2 will give usadditional insights into the pathogenesis for a number of
MNDs caused by the ALS2 mutations.
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